Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy
20. April 2016 09:00 ET
|
Alectos Therapeutics Inc.
VANCOUVER, BRITISH COLUMBIA, April 20, 2016 (GLOBE NEWSWIRE) -- Alectos Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...